Endocrine Abstracts

Neuroendocrine gastro-enteropancreatic tumors constitute a diverse group of malignant neoplasms with a common feature of hormone production and release. The incidence and prevalence have constantly increased over the last decades with an incidence of about 6/100 000 and a prevalence of 35/100 000 inhabitants. The majority of patients present a metastatic disease at diagnosis. The most common subtypes of GEP-NETs are small intestinal NETs (carcinoids) followed by pancreatic and...

Neuroendocrine tumors of the GI-tract have attained increased attention during the last decades. The incidence of these rare neoplasms is about 2.5-4.0 per 100.000 per year.The most significant developments within the management of neuroendocrine GI-tumors have been in the areas of histopathology, tumor markers, localisation procedures and treatment. A new WHO-classification system has emerged which not only classify the tumor as neuroendocrine, but also...

Background: The phase III, placebo-controlled, randomized TELESTAR study evaluated efficacy and safety of telotristat ethyl (TE) in patients (pts) with diarrhoea (≥4 bowel movements (BMs)/day) due to carcinoid syndrome (CS) inadequately controlled by somatostatin analogs (SSAs). TE, a tryptophan hydroxylase inhibitor, decreases peripheral serotonin levels. As add-on treatment to SSAs, TE 250 mg 3x/day (tid) and TE 500 mg tid significantly reduced BM frequency (P...

Background: Currently, there are limited therapeutic options for patients with advanced midgut neuroendocrine tumors progressing on first-line somatostatin analog therapy.Methods: NETTER-1 is the first phase III, randomized trial evaluating 177Lu-DOTA0-Tyr3-Octreotate (Lutathera®) in patients with progressive, somatostatin receptor positive midgut NETs. 230 patients were randomized to receive Lutathera 7.4...

Introduction: TELESTAR was a pivotal, randomized phase 3 study evaluating telotristat etiprate (TE), a tryptophan hydroxylase inhibitor, among patients (pts) with carcinoid syndrome (CS). When added to somatostatin analogues (SSA), 250 mg tid and 500 mg tid TE each produced significantly greater bowel movement (BM) frequency reduction averaged over 12 weeks (wks) than placebo (PBO) plus SSA (P<0.001). Pts crossed over to open-label (OL) treatment with TE 500 mg ti...